All right, so welcome back to the IBCC podcast.

I'm here with Adam Thomas and we're going to dip our feedback into the COVID update topic.

It's been a bit.

Josh, we took a bit of a break, but I think there's a lot of things going on that we definitely

need to get back into it, don't we?

Yeah. It's pretty interesting looking at the amount of evidence that has accumulated over

the last couple months and, you know, there's a lot of evidence and also in some ways things

haven't changed a whole lot.

So today, let's update around some therapeutics and some prognostication and then

aerosol transmission.

So you want to get straight into it, don't you, Josh?

Let's get into transmission stuff, shall we say?

Start us off with, we know distancing in masks, but should I be quiet?

I think what kind of tipped this whole topic over a little bit recently was the Damask trial, which is an

RCT, of whether or not masks could reduce transmission. And the trial did not show a benefit

or obviously a detriment for masks, but it was super underpowered and had a lot of technical

problems with it. But this kind of unleashed a new debate about aerosol transmission and masking on Twitter.

Unleased debate is correct.

And I think the discourse is worth it.

But what I would say is knowing that it's a public forum, that discourse could be misconstrued sometimes, can it, Josh?

Yeah.

And this is so challenging because honestly, I've lost track of exactly what we're doing.

...